Hong Qiu

Global Epidemiology, Office of Chief Medical Officer, Johnson & Johnson, USA

Poster(s):

• (015) Discordance between clinical and pathological stage in non-small cell lung cancer patients in China
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (019) Initial and subsequent biological therapies for patients with psoriasis vulgaris during 2010-2021 in Japan
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (034) Scoping Review of the Use of Post-marketing Database Studies (PMDS) as an Additional Pharmacovigilance Activity of Risk Management Plans in Japan
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST

• (080) The treatment modalities and radiotherapy pattern in patients of primary lung cancer with distant metastasis in Japan
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (300) Antipsychotics in treatment of adolescents with schizophrenia in China
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (306) Development of matching procedures to identify comparators for real-world comparative evaluations of antipsychotics
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (CSPOT05) Effect of long-acting injectable antipsychotics on treatment adherence and healthcare utilization in Chinese patients with schizophrenia: 1-year mirror-image study
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST